Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity

Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity

We have demonstrated that the angiotensin-converting enzyme (ACE) genotype is associated with Alzheimer's disease (AD) in the Japanese population (1Hu J. Miyatake F. Aizu Y. Nakagawa H. Nakamura S. Tamaoka A. Takahashi R. Urakami K. Shoji M. Neurosci. Lett. 1999; 277: 65-67Crossref PubMed Scopu...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Jianguo Hu, Akira Igarashi, Makiko Kamata, Hachiro Nakagawa
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2001
Urunga tuihono:	https://doi.org/10.1074/jbc.m104068200 http://www.jbc.org/article/S0021925819402937/pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

The N‐terminal active centre of human angiotensin‐converting enzyme degrades Alzheimer amyloid β‐peptide
mā: Ryutaro Oba, me ētahi atu.
I whakaputaina: (2005)

Angiotensin-Converting Enzyme Converts Amyloid β-Protein 1–42 (Aβ(1–42)) to Aβ(1–40), and Its Inhibition Enhances Brain Aβ Deposition
mā: Zou, Kun, me ētahi atu.
I whakaputaina: (2007)

Charge Dependent Retardation of Amyloid β Aggregation by Hydrophilic Proteins
mā: Assarsson, Anna, me ētahi atu.
I whakaputaina: (2014)

Charge Dependent Retardation of Amyloid β Aggregation by Hydrophilic Proteins
mā: Anna Assarsson, me ētahi atu.
I whakaputaina: (2014)

New Insights on How Metals Disrupt Amyloid β-Aggregation and Their Effects on Amyloid-β Cytotoxicity
mā: Yuji Yoshiike, me ētahi atu.
I whakaputaina: (2001)

Angiotensin-Converting Enzyme Converts Amyloid β-Protein 1–42 (Aβ<sub>1–42</sub>) to Aβ<sub>1–40</sub>, and Its Inhibition Enhances Brain Aβ Deposition
mā: Kun Zou, me ētahi atu.
I whakaputaina: (2007)

Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors
mā: Wisniewski, Thomas, me ētahi atu.
I whakaputaina: (2008)

Zinc as chaperone-mimicking agent for retardation of amyloid β peptide fibril formation
mā: Abelein, Axel, me ētahi atu.
I whakaputaina: (2015)

Zinc as chaperone-mimicking agent for retardation of amyloid β peptide fibril formation
mā: Axel Abelein, me ētahi atu.
I whakaputaina: (2015)

Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles
mā: Joshi, P, me ētahi atu.
I whakaputaina: (2014)

Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles
mā: P. Joshi, me ētahi atu.
I whakaputaina: (2013)

Aβ42-to-Aβ40- and Angiotensin-converting Activities in Different Domains of Angiotensin-converting Enzyme
mā: Zou, Kun, me ētahi atu.
I whakaputaina: (2009)

Aβ42-to-Aβ40- and Angiotensin-converting Activities in Different Domains of Angiotensin-converting Enzyme
mā: Kun Zou, me ētahi atu.
I whakaputaina: (2009)

TMPyP Inhibits Amyloid-β Aggregation and Alleviates Amyloid-Induced Cytotoxicity
mā: Fan, Yujuan, me ētahi atu.
I whakaputaina: (2017)

Regulation of Steady-state β-Amyloid Levels in the Brain by Neprilysin and Endothelin-converting Enzyme but Not Angiotensin-converting Enzyme
mā: Elizabeth A. Eckman, me ētahi atu.
I whakaputaina: (2006)

The Serpin-Enzyme Complex Receptor Recognizes Soluble, Nontoxic Amyloid-β Peptide but Not Aggregated, Cytotoxic Amyloid-β Peptide
mā: Kimberly Boland, me ētahi atu.
I whakaputaina: (1996)

TDP-43 expression influences amyloid β plaque deposition and tau aggregation
mā: Davis, Stephani A., me ētahi atu.
I whakaputaina: (2017)

TDP-43 expression influences amyloidβ plaque deposition and tau aggregation
mā: Stephani A. Davis, me ētahi atu.
I whakaputaina: (2017)

Reduced Lipid Bilayer Thickness Regulates the Aggregation and Cytotoxicity of Amyloid-β
mā: Korshavn, Kyle J., me ētahi atu.
I whakaputaina: (2017)

Reduced Lipid Bilayer Thickness Regulates the Aggregation and Cytotoxicity of Amyloid-β
mā: Kyle J. Korshavn, me ētahi atu.
I whakaputaina: (2017)

The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation
mā: Garai, Kanchan, me ētahi atu.
I whakaputaina: (2014)

The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation
mā: Kanchan Garai, me ētahi atu.
I whakaputaina: (2014)

Conversion of Aβ43 to Aβ40 by the successive action of angiotensin‐converting enzyme 2 and angiotensin‐converting enzyme
mā: Shuyu Liu, me ētahi atu.
I whakaputaina: (2014)

Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity
mā: Du, Wen-Jie, me ētahi atu.
I whakaputaina: (2015)

Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity
mā: Wenjie Du, me ētahi atu.
I whakaputaina: (2015)

Cytotoxicity of Amyloid β1–42 Fibrils to Brain Immune Cells
mā: Mikhail Matveyenka, me ētahi atu.
I whakaputaina: (2025)

Tanshinones Inhibit Amyloid Aggregation by Amyloid-β Peptide, Disaggregate Amyloid Fibrils, and Protect Cultured Cells
mā: Wang, Qiuming, me ētahi atu.
I whakaputaina: (2013)

Tanshinones Inhibit Amyloid Aggregation by Amyloid-β Peptide, Disaggregate Amyloid Fibrils, and Protect Cultured Cells
mā: Qiuming Wang, me ētahi atu.
I whakaputaina: (2013)

Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor
mā: Hemming, Matthew L., me ētahi atu.
I whakaputaina: (2005)

Kinetic and structural characterization of amyloid‐β peptide hydrolysis by human angiotensin‐1‐converting enzyme
mā: Larmuth, Kate M., me ētahi atu.
I whakaputaina: (2016)

Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor
mā: Matthew L. Hemming, me ētahi atu.
I whakaputaina: (2005)

A New Motif in the N‐Terminal of Acetylcholinesterase Triggers Amyloid‐β Aggregation and Deposition
mā: Hou, Li‐Na, me ētahi atu.
I whakaputaina: (2013)

Amyloid-β(1–42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity
mā: Jin, Sha, me ētahi atu.
I whakaputaina: (2016)

Amyloid-β(1–42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity
mā: Sha Jin, me ētahi atu.
I whakaputaina: (2016)

β‐Amyloid aggregation and heterogeneous nucleation
mā: Srivastava, Atul K., me ētahi atu.
I whakaputaina: (2019)

β‐Amyloid aggregation and heterogeneous nucleation
mā: Atul Srivastava, me ētahi atu.
I whakaputaina: (2019)

Aggregation and structure of amyloid β-protein
mā: Kenjiro Ono, me ētahi atu.
I whakaputaina: (2021)

Inhibition of Amyloid β Protein Aggregation and Neurotoxicity by Rifampicin
mā: Takami Tomiyama, me ētahi atu.
I whakaputaina: (1996)

Heparin Nanoparticles for β Amyloid Binding and Mitigation of β Amyloid Associated Cytotoxicity
mā: Wang, Peng, me ētahi atu.
I whakaputaina: (2014)

Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology
mā: Kehoe, Patrick Gavin, me ētahi atu.
I whakaputaina: (2016)